Tezspire Meets Both Phase III Endpoints in Eosinophilic Esophagitis

Companies: AstraZeneca / Amgen · Drug: Tezspire (Tezepelumab) · Trial: CROSSING (Phase III) · Indication: Eosinophilic Esophagitis · Date: August 27, 2026 Summary AstraZeneca and Amgen reported that the 368-patient Phase III CROSSING trial of tezepelumab in eosinophilic esophagitis met both co-primary endpoints at Week…